Literature DB >> 30327186

The devil is in the details: Assessing treatment and outcomes of 6,795 patients undergoing remedial parathyroidectomy in the Collaborative Endocrine Surgery Quality Improvement Program.

Hadiza S Kazaure1, Samantha Thomas2, Randall P Scheri3, Michael T Stang3, Sanziana A Roman3, Julie A Sosa3.   

Abstract

BACKGROUND: Multi-institutional data describing remedial parathyroidectomy compared with index parathyroidectomy are scarce.
METHODS: Using data in the Collaborative Endocrine Surgery Quality Improvement Program (2014-2017), baseline characteristics and outcomes of patients undergoing remedial parathyroidectomy versus index parathyroidectomy were examined using bivariate and multivariate methods. Rates of hypercalcemia and hypocalcemia at ≥ 180 days were assessed.
RESULTS: Among 6,795 patients, 367 (5.4%) underwent remedial parathyroidectomy. A single localization study was done in 24.8% versus 26.9% of remedial parathyroidectomy versus index parathyroidectomy (P = .37). Patients undergoing remedial parathyroidectomy had higher rates of preoperative laryngoscopy (45.5% versus 6.2%, P < .001), intraoperative nerve monitoring (57.5% versus 34.5%, P < .001), and < 50% drop in hyperparathyroidism than those undergoing index parathyroidectomy (9.6% versus 3.3%, P < .001). Among patients with ≥ 180 days follow-up, none of the remedial parathyroidectomy versus three index parathyroidectomy patients (0.3%) had vocal cord dysfunction. Hypercalcemia rates for remedial parathyroidectomy and index parathyroidectomy were 10.5% versus 5.0 (P = .07), and hypocalcemia rates were 10.5% versus 2.4% (P < .001). After multivariate adjustment, failure to cure was 4.0 times more likely in remedial parathyroidectomy than index parathyroidectomy (P < .001).
CONCLUSION: This is the first multi-institutional examination of remedial parathyroidectomy outcomes in the Collaborative Endocrine Surgery Quality Improvement Program. Nerve injury rates are low; high rates of hypercalcemia and hypocalcemia suggest potential opportunities to refine the preoperative and intraoperative management of patients undergoing remedial parathyroidectomy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30327186     DOI: 10.1016/j.surg.2018.03.026

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  4D-Dynamic Contrast-Enhanced MRI for Preoperative Localization in Patients with Primary Hyperparathyroidism.

Authors:  J L Becker; V Patel; K J Johnson; M Guerrero; R R Klein; G F Ranvier; R P Owen; P Pawha; K Nael
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

2.  Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK).

Authors:  T Weber; C Dotzenrath; H Dralle; B Niederle; P Riss; K Holzer; J Kußmann; A Trupka; T Negele; R Kaderli; E Karakas; F Weber; N Rayes; A Zielke; M Hermann; C Wicke; R Ladurner; C Vorländer; J Waldmann; O Heizmann; S Wächter; S Schopf; W Timmermann; D K Bartsch; R Schmidmaier; M Luster; K W Schmid; M Ketteler; C Dierks; P Schabram; T Steinmüller; K Lorenz
Journal:  Langenbecks Arch Surg       Date:  2021-04-21       Impact factor: 3.445

Review 3.  Recent advances in the understanding and management of primary hyperparathyroidism.

Authors:  Melanie Goldfarb; Frederick R Singer
Journal:  F1000Res       Date:  2020-02-25

Review 4.  A Review of Parathyroid Surgery for Primary Hyperparathyroidism from the United Kingdom Registry of Endocrine and Thyroid Surgery (UKRETS).

Authors:  H Ishii; M J Stechman; J C Watkinson; S Aspinall; D S Kim
Journal:  World J Surg       Date:  2020-12-02       Impact factor: 3.352

5.  18F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism.

Authors:  Adrien Latge; Sophie Riehm; Michel Vix; Jacob Bani; Mihaela Ignat; Valentin Pretet; Mehdi Helali; Giorgio Treglia; Alessio Imperiale
Journal:  Diagnostics (Basel)       Date:  2021-12-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.